STOCK TITAN
  1. Home
  2. News
  3. CDNA

CareDx, Inc. - CDNA STOCK NEWS

Welcome to our dedicated page for CareDx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on CareDx stock.

CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.

CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.

The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.

CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.

Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.

News

CareDx to Report First Quarter 2024 Financial Results

Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA) will report financial results for the first quarter of 2024, focusing on healthcare solutions for transplant patients. The conference call will take place on May 9, 2024, providing insights for investors and interested parties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
conferences earnings
-
News

CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
CareDx, a precision medicine company, granted an option to purchase 700,706 shares of common stock and 487,804 restricted stock units to its new President and CEO, John Hanna. The option has an exercise price of $8.20 and will vest over four years, while the RSUs will vest in four equal, annual installments beginning on April 15, 2025. This grant was approved by the board of directors as an inducement material to Mr. Hanna's employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
-
News

CareDx Appoints John W. Hanna as its New President and Chief Executive Officer

Rhea-AI Summary
CareDx, Inc. appoints John W. Hanna as the new President and CEO, bringing over two decades of executive leadership experience in the molecular diagnostics and life sciences tools industries. Hanna aims to drive sustainable growth and innovation at CareDx, focusing on improving patient outcomes and expanding the company's product portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
management
News

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) announces presentation of latest data at ISHLT 44th Annual Meeting showcasing benefits of surveillance with HeartCare. The company will highlight developments in its cardiothoracic portfolio, including AlloSure Heart, AlloMap Heart, HeartCare, AlloSure Lung, and AiCAV. Leading experts will discuss the use of these technologies in heart and lung transplantation, emphasizing the clinical utility of surveillance testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.41%
Tags
none
-
News

CareDx Appoints Bryan Riggsbee to Its Board of Directors

Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) welcomes Bryan Riggsbee to its Board of Directors, bringing financial expertise and experience from Myriad Genetics and LabCorp. Riggsbee's background in revenue cycle management and molecular diagnostics will enhance CareDx's strategic growth and business development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
management
-
News

CareDx Announces Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
CareDx, Inc. (CDNA) reported total revenue of $280.3 million for 2023, surpassing updated guidance. The company achieved growth in Testing Services for the second consecutive quarter, with $209.7 million in revenue. Despite challenges, they ended the year with $235.4 million in cash and securities, repurchased shares, and received Medicare coverage for key products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.47%
Tags
earnings
News

CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference

Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) to participate in Raymond James & Associates’ 45th Annual Institutional Investors Conference. The company will present on March 6, 2024, focusing on precision medicine for transplant patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
-
News

CareDx to Report Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
CareDx, Inc. (CDNA) will report financial results for Q4 and full year 2023 on February 28, 2024. The company focuses on healthcare solutions for transplant patients and caregivers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
conferences earnings
-
News

CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) announces its participation in the 2024 Tandem Meetings to showcase its digital solutions and advancements in cellular therapy and transplant monitoring. The company will present data on AlloHeme and AlloCell at the event, highlighting their potential in treatment response monitoring and relapse detection post-transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
News

CareDx Issues Statement in Patent Infringement Case

Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) has been found to have not infringed on Natera, Inc.'s patent 10,655,180 but was found to have infringed on patent 11,111,544. The District of Delaware jury awarded Natera damages of $83,679,521 in lost profits and $12,535,500 in past royalties for alleged infringement by AlloSure from September 2021 through August 2023. CareDx intends to seek judicial review of the verdict. The decision does not impact patient or physician access to CareDx's current offerings, including AlloSure or AlloMap.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.53%
Tags
none

FAQ

What is the current stock price of CareDx (CDNA)?

The current stock price of CareDx (CDNA) is $22.58 as of November 21, 2024.

What is the market cap of CareDx (CDNA)?

The market cap of CareDx (CDNA) is approximately 1.2B.

What does CareDx, Inc. specialize in?

CareDx, Inc. specializes in precision medicine and surveillance management solutions aimed at improving the lives of organ transplant patients.

What is AlloSure®?

AlloSure® is a non-invasive blood test that measures allograft injury and detects donor-derived cell-free DNA (dd-cfDNA) to identify organ injury in kidney transplant patients.

Which organs do CareDx's products focus on?

CareDx's products focus on kidney, heart, and lung transplants.

Where does CareDx generate most of its revenue?

CareDx generates the majority of its revenue from the United States, primarily through its testing services.

What are some key products offered by CareDx?

Key products include AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung, all of which are dd-cfDNA solutions.

How does CareDx support transplant patients?

CareDx supports transplant patients by offering non-invasive diagnostic tests that help in monitoring and managing organ transplant health.

What technology does CareDx use in its diagnostics?

CareDx uses genomics and bioinformatics technology, specifically next-generation sequencing (NGS) to develop its diagnostic tests.

Does CareDx collaborate with other healthcare institutions?

Yes, CareDx partners with leading healthcare institutions to validate and implement their diagnostic solutions.

What kind of clinical evidence does CareDx generate?

CareDx generates high-quality clinical evidence through trials and registries to support the efficacy of its products.

What makes CareDx a leader in transplant diagnostics?

CareDx's combination of innovative diagnostic solutions, clinical evidence, and partnerships positions it as a leader in transplant diagnostics and surveillance.

Stock CDNA logo
CareDx, Inc.

Nasdaq:CDNA

CDNA Rankings

#2395 Ranked by Market Cap
N/A Ranked by Dividends

CDNA Stock Data

1.20B
51.79M
3.44%
96.1%
6.43%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
BRISBANE